Core Insights - Prenetics Global Limited is actively participating in upcoming investor conferences, showcasing its commitment to investor engagement and transparency [2][3]. Group 1: Investor Conferences - The company will attend The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025, where CEO Danny Yeung will hold one-on-one meetings with investors [2]. - Prenetics will also participate in Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, with a formal presentation by CEO Danny Yeung on December 10 at 10:00 a.m. Eastern Time, followed by one-on-one meetings with CFO Stephen Lo [3]. Group 2: Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved $108 million in Annual Recurring Revenue (ARR) within 12 months of launch, marking the fastest growth in the supplement industry [5]. - The company has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 501 BTC as of November 24, 2025, indicating its innovative approach at the intersection of health and digital assets [6]. Group 3: IM8 Brand - IM8, co-founded with David Beckham, offers a premium core nutrition product, Daily Ultimate Essentials, which replaces 16 different supplements in a single drink and is NSF Certified for Sport, non-GMO, and vegan [7].

Core Insights - Prenetics Global Limited, a health-tech and longevity company, has announced that its executive leadership team has made open market purchases of the company's common stock, indicating strong internal confidence in the company's future [1][5]. Executive Purchases - The executive team collectively acquired 111,911 shares for approximately $1,446,887 [2]. - CEO Danny Yeung purchased 40,118 shares for about $502,000 at an average price of $12.51 per share [3]. - CMO Rahul Ramchand bought 60,000 shares for approximately $793,972 at an average price of $13.23 per share [4]. - CFO Stephen Lo acquired 8,000 shares for about $100,915 at an average price of $12.61 per share [4]. - President of Americas David Vanderveen purchased 3,793 shares for approximately $50,000 at an average price of $13.15 per share [5]. Company Overview - Prenetics is a leading health sciences company focused on redefining health and longevity through its flagship brand IM8, co-founded with David Beckham [6]. - IM8 has achieved $100 million in Annual Recurring Revenue within 11 months of launch, marking the fastest growth in the supplement industry [6]. - Prenetics is the first consumer health company to establish a Bitcoin treasury, currently holding 501 BTC, and purchases 1 Bitcoin daily [7]. Product Information - IM8 offers a premium core nutrition product, Daily Ultimate Essentials, which is an all-in-one powder supplement designed to replace 16 different supplements [8].

Core Insights - Cantor Fitzgerald has reiterated its Overweight rating on Prenetics Global Limited, adjusting the 12-month price target to $31 from $32, reflecting updates related to the planned divestment of its Europa business while maintaining a positive long-term outlook on the company [1][2] Financial Performance - Prenetics reported a 3Q25 revenue of $23.6 million, representing approximately 568% year-over-year growth, with IM8 revenue reaching $17.2 million, up about 76% sequentially and achieving gross margins of around 60% [5] - The company has a customer payback period of approximately 3.9 months and an 80%+ subscription rate, indicating strong unit economics [5] - As of November 10, 2025, Prenetics holds approximately 387 BTC valued at around $41 million, contributing to total liquidity of approximately $120 million [5] Market Position and Valuation - Cantor views Prenetics as undervalued, with PRE trading at just 0.7× EV/2026E revenue compared to approximately 1.1× for consumer-health peers [2] - Cantor forecasts FY2026 revenue of approximately $217 million, driven by continued momentum from IM8 and international expansion [5] Management Commentary - CEO Danny Yeung emphasized that Cantor's ongoing research coverage highlights Prenetics' emergence as a global leader in health and longevity, reinforcing investor understanding of the significant opportunities ahead as IM8 scales internationally [2]

Financial Data and Key Metrics Changes - Total revenue surged 568% year over year to $23.6 million in Q3 2025, driven by IMA's 76% quarter-to-quarter growth [9] - Adjusted EBITDA loss improved from $6.5 million in Q1 to $2.1 million in Q3, indicating operational leverage and a clear path to profitability [12][17] - Cash increased to approximately $82 million and Bitcoin holdings valued at around $40 million, resulting in total liquidity of about $120 million with zero debt [7][18] Business Line Data and Key Metrics Changes - IMA achieved $100 million annual recurring revenue (ARR) in the last 11 months, with projections to reach $300 million ARR by the end of 2026 [6] - Subscription rate for IMA stands at 80%, with an average order value increasing by 36% quarter over quarter to $150 [10][11] - Gross margin improved to 60% from 52%, reflecting enhanced profitability [10] Market Data and Key Metrics Changes - International markets now account for 56.5% of total revenue, with the U.S. being the top market followed by Canada, the U.K., Australia, and Singapore [10] - IMA has achieved over 420,000 customer purchases across 31 countries, indicating strong global demand [9] Company Strategy and Development Direction - The company aims to create a new category at the intersection of health and wealth, targeting $1 billion in annual revenue by 2030 [6] - A strategic divestment of non-core assets is underway to focus resources on IMA, the highest margin growth engine [14] - The company is leveraging partnerships with high-profile individuals to enhance brand visibility and credibility [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $180-$200 million in revenue for 2026, driven by international expansion and new product launches [18] - The company is strategically choosing to scale aggressively rather than prioritize short-term profitability, aiming to capture maximum market share [18] Other Important Information - The company has initiated a Bitcoin accumulation strategy, purchasing one Bitcoin daily since August 1, which is part of a sustainable framework to build shareholder value [8] - The recent $44 million funding round attracted notable investors, enhancing the company's financial position [6] Q&A Session Summary Question: Impressive payback period of 3.9 months - Management explained that the payback period has improved from four to five months at launch to 3.9 months now, indicating marketing efficiencies and strong unit economics [19][20] Question: Strong growth in international markets - Management noted that the U.S. market share has decreased from 70% to 46.5%, with significant growth observed in Canada, Europe, the Middle East, and Southeast Asia [21] Question: Need for additional capital for expansion - Management stated that with current liquidity, there is no expectation of needing new capital for expansion, emphasizing operational flexibility from recent fundraising [22][24]

Core Insights - Prenetics Global Limited has launched Daily Ultimate Longevity, a supplement targeting all 12 hallmarks of aging, reinforcing IM8's rapid growth in the supplement industry [1][3][4] - IM8 has achieved a compound annual growth rate of 2,457%, with monthly revenue increasing from approximately $600,000 to $6.6 million within nine months [1][4] - The global longevity market is projected to reach $314 billion by 2030, positioning IM8 at the forefront of this expanding market [7] Company Overview - Prenetics is a leading consumer health sciences company, with IM8 being one of the fastest-growing supplement brands co-founded by David Beckham [1][11] - The company maintains a strong financial foundation with over $90 million in liquid assets, including approximately $60 million in cash and 255.4 Bitcoin valued at around $31.6 million [10] Product Details - Daily Ultimate Longevity is formulated with IM8's proprietary 5-Complex System, delivering therapeutic doses of clinically-validated ingredients in a powder format [3][5][8] - The product is designed to target key aging pathways such as cellular senescence and mitochondrial dysfunction, supported by human clinical research [5][6][8] - It is priced at $149 for a one-time purchase and $119 per month for subscription, reflecting its premium positioning in the market [9] Market Positioning - The launch of Daily Ultimate Longevity is seen as a category-defining innovation in the rapidly growing longevity market [7][8] - The product's formulation includes high-dose glycine, taurine, and other key ingredients aimed at comprehensive cellular support and energy enhancement [8][12]

Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]

Core Insights - IM8 hosted an event called IM8 Vibrante to promote its vision of making elite wellness accessible to all, featuring nearly 150 attendees including wellness influencers and medical advisors [1][2] - The event highlighted IM8's commitment to blending science and holistic health, showcasing its flagship product, Daily Ultimate Essentials, which is designed to replace 16 different supplements [7] Company Overview - IM8 is co-founded by David Beckham and focuses on premium core nutrition, combining advanced science with natural ingredients to promote health [7] - The flagship product, Daily Ultimate Essentials, is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, and sweeteners [7] Event Highlights - David Beckham shared his personal wellness journey and the positive impact of IM8 on his energy and focus [3] - A panel discussion featured experts discussing longevity and healthspan, emphasizing the importance of quality of life alongside lifespan [3] - Dr. Jim Green presented ongoing research on advanced aging in space, in collaboration with Oxford University and SpaceX [3] Community Engagement - The event underscored the strength of the IM8 ambassador and creator community, which plays a vital role in promoting wellness and engaging audiences [5] - Influencers from platforms like TikTok and Meta showcased their commitment to wellness, aligning with IM8's mission [5] Leadership Perspective - Danny Yeung, CEO of IM8, expressed pride in the progress made and the inspiring energy of the community at the event [6]